ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
SEK 19.62
(0.2%)
SEK 19.62
(0.2%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 78.69 Million SEK | -42.71% |
| 2022 | 137.36 Million SEK | -9.6% |
| 2021 | 151.95 Million SEK | 27.85% |
| 2020 | 118.85 Million SEK | 535.37% |
| 2019 | 18.7 Million SEK | -10.72% |
| 2018 | 20.95 Million SEK | 21.58% |
| 2017 | 17.23 Million SEK | -29.98% |
| 2016 | 24.61 Million SEK | 501.51% |
| 2015 | 4.09 Million SEK | -25.35% |
| 2014 | 5.48 Million SEK | 33.48% |
| 2013 | 4.1 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 94 Million SEK | 9.12% |
| 2024 Q1 | 86.14 Million SEK | 9.47% |
| 2023 Q3 | 101.92 Million SEK | -12.07% |
| 2023 Q4 | 78.69 Million SEK | -22.79% |
| 2023 Q1 | 103.12 Million SEK | -24.93% |
| 2023 Q2 | 115.9 Million SEK | 12.4% |
| 2023 FY | 78.69 Million SEK | -42.71% |
| 2022 Q1 | 140.03 Million SEK | -7.85% |
| 2022 FY | 137.36 Million SEK | -9.6% |
| 2022 Q4 | 137.36 Million SEK | -19.43% |
| 2022 Q3 | 170.49 Million SEK | -9.54% |
| 2022 Q2 | 188.48 Million SEK | 34.59% |
| 2021 Q1 | 98.08 Million SEK | -17.48% |
| 2021 Q3 | 159.42 Million SEK | 24.17% |
| 2021 Q2 | 128.39 Million SEK | 30.91% |
| 2021 FY | 151.95 Million SEK | 27.85% |
| 2021 Q4 | 151.95 Million SEK | -4.69% |
| 2020 FY | 118.85 Million SEK | 535.37% |
| 2020 Q1 | 22.1 Million SEK | 18.14% |
| 2020 Q2 | 28.29 Million SEK | 28.01% |
| 2020 Q3 | 42.91 Million SEK | 51.69% |
| 2020 Q4 | 118.85 Million SEK | 176.95% |
| 2019 Q3 | 18.54 Million SEK | -12.75% |
| 2019 FY | 18.7 Million SEK | -10.72% |
| 2019 Q4 | 18.7 Million SEK | 0.86% |
| 2019 Q2 | 21.25 Million SEK | -12.07% |
| 2019 Q1 | 24.17 Million SEK | 15.38% |
| 2018 FY | 20.95 Million SEK | 21.58% |
| 2018 Q2 | 29.76 Million SEK | -12.5% |
| 2018 Q4 | 20.95 Million SEK | -16.0% |
| 2018 Q1 | 34.02 Million SEK | 97.4% |
| 2018 Q3 | 24.94 Million SEK | -16.2% |
| 2017 Q2 | 19.9 Million SEK | -11.35% |
| 2017 Q1 | 22.45 Million SEK | -8.79% |
| 2017 Q4 | 17.23 Million SEK | -15.8% |
| 2017 FY | 17.23 Million SEK | -29.98% |
| 2017 Q3 | 20.47 Million SEK | 2.85% |
| 2016 Q1 | 4.12 Million SEK | 0.0% |
| 2016 Q4 | 24.61 Million SEK | -11.51% |
| 2016 Q3 | 27.81 Million SEK | -11.15% |
| 2016 Q2 | 31.3 Million SEK | 658.98% |
| 2016 FY | 24.61 Million SEK | 501.51% |
| 2015 FY | 4.09 Million SEK | -25.35% |
| 2014 FY | 5.48 Million SEK | 33.48% |
| 2013 FY | 4.1 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | 36.121% |
| Amniotics AB (publ) | 26.08 Million SEK | -201.664% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -1194.915% |
| BioArctic AB (publ) | 1.18 Billion SEK | 93.365% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 95.86% |
| Genovis AB (publ.) | 288.85 Million SEK | 72.757% |
| LIDDS AB (publ) | 17.65 Million SEK | -345.721% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 71.769% |
| OncoZenge AB (publ) | 20.34 Million SEK | -286.883% |
| Saniona AB (publ) | 64.14 Million SEK | -22.682% |
| Simris Alg AB (publ) | 174.55 Million SEK | 54.918% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 84.143% |
| AcouSort AB (publ) | 34.51 Million SEK | -128.007% |
| Active Biotech AB (publ) | 44 Million SEK | -78.845% |
| Camurus AB (publ) | 1.9 Billion SEK | 95.875% |
| Cantargia AB (publ) | 223.71 Million SEK | 64.824% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -429.235% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 7.668% |
| Mendus AB (publ) | 755.95 Million SEK | 89.59% |
| Kancera AB (publ) | 65.64 Million SEK | -19.879% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 93.747% |
| Lipum AB (publ) | 12.11 Million SEK | -549.81% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -134.188% |
| NextCell Pharma AB | 81.28 Million SEK | 3.194% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 87.959% |
| Xintela AB (publ) | 18.39 Million SEK | -327.79% |
| Ziccum AB (publ) | 14.97 Million SEK | -425.594% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -160.802% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -292.655% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 44.03% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 89.717% |
| CombiGene AB (publ) | 120.61 Million SEK | 34.756% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 63.743% |
| Intervacc AB (publ) | 259.61 Million SEK | 69.688% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 33.565% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -26.155% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -87.545% |
| Corline Biomedical AB | 100.1 Million SEK | 21.391% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 55.572% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -26.612% |
| Aptahem AB (publ) | 63.02 Million SEK | -24.859% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 77.602% |
| Fluicell AB (publ) | 9.34 Million SEK | -742.527% |
| Biovica International AB (publ) | 131.4 Million SEK | 40.116% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -48.518% |
| Abliva AB (publ) | 87.49 Million SEK | 10.065% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 89.649% |
| 2cureX AB (publ) | 16.62 Million SEK | -373.335% |
| I-Tech AB | 152.44 Million SEK | 48.379% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 92.27% |
| Cyxone AB (publ) | 43.65 Million SEK | -80.259% |
| Biosergen AB | 7.2 Million SEK | -992.793% |
| Nanologica AB (publ) | 77.42 Million SEK | -1.631% |
| SynAct Pharma AB | 228.01 Million SEK | 65.489% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -194.033% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 94.38% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -262.588% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 66.989% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -830.716% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 9.624% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -176.035% |